

	FENOFIBRATE	GEMFIBROZIL
Trade names	TRICOR	LOPID
Class	Hypertriglyceridemia	Hypertriglyceridemia
Adult Dose	Hypertriglyceridemia: 48 mg daily Dose adjusted every 8 weeks after lipid tests, MAX 145 mg/day Or Micronized 67 mg to 200 mg	Hyperlipidemia: 600 mg ORALLY twice daily Reduction of coronary risk: 600 mg ORALLY twice daily
Dose Adjustments	Geriatric and renal failure: starting dose 67 mg orally daily.	Renal impairment: lower doses may be appropriate, though some studies have concluded that dose reductions are not needed
Monitoring	Lipid levels Liver enzymes Periodic blood counts during first 12 months	Serum lipids Periodic blood counts recommended during first 12 months of therapy Measure creatine kinase in patients with symptomatic myopathy
Contraindications	Pre-existing gallbladder disease Hypersensitivity to fenofibrate products Hepatic dysfunction, including primary biliary cirrhosis and unexplained persistent liver function abnormality	Coadministration with gemfibrozil and other statins Gallbladder disease Hepatic dysfunction, including biliary cirrhosis Hypersensitivity to gemfibrozil
Precautions	Co-administration with anticoagulants or HMG CoA reductase inhibitors Myalgia Pancreatitis	Cholelithiasis Concomitant use of anticoagulants Concomitant use of HMG-coa reductase inhibitors Hypothyroidism Cataracts
Efficacy	Total C - 22% TG - 54% HDL +9% LDL ±10% Fibrinogen -13% Uric acid -17%	Total C - 23% TG - 65% HDL +16% LDL ±10% Fibrinogen -5% Uric acid +1%
Adverse Effects	Common Diarrhea, flatulence Muscle pain Nausea/vomiting Rash Rhinitis	Common Abdominal pain Diarrhea, flatulence Dyspepsia Muscle pain Rash

	FENOFIBRATE	GEMFIBROZIL
	Serious Hepatotoxicity (rare) Rhabdomyolysis (rare) Pancreatitis (rare)	Serious Abnormal liver function tests Rhabdomyolysis (especially when coadministered with a statin)
Drug Interactions	cholestyramine ezetimibe Statins warfarin	Statins ezetimibe glyburide repaglinide rosiglitazone rosuvastatin warfarin
Cost	98.57/month	11.60/ month

